Efficiently Creating Value with Innovative Science


NASDAQ: OXGN

$ 1.42 0.02 (1.39%)
Day High: 1.46
Day Low:  1.40
Volume:    274,800
4:00 PM ET
May 22, 2015

Delayed ~20 min., by eSignal.

Press Releases

 
Press Releases
Date Title and Summary View
May 12, 2015 SOUTH SAN FRANCISCO, Calif., May 12, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced the appointment of a new President and Chief Executive Officer, Bill Schwieterman, M.D. The company's current CEO, Dai Chaplin, Ph.D., will become Chief ...
Apr 30, 2015 SOUTH SAN FRANCISCO, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, reported financial results for the quarter ended March 31, 2015. "We continue to make good progress toward achieving our goals for 2015, which are focused on a...
Apr 20, 2015 SOUTH SAN FRANCISCO, Calif., April 20, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced that it will report first quarter 2015 financial results on Thursday, April 30, 2015. A conference call and webcast hosted by OXiGENE management will b...
Apr 2, 2015 SOUTH SAN FRANCISCO, Calif., April 2, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced that the company will participate in two upcoming investor and medical conferences. 14th Annual Needham Healthcare Conference Dai Chapli...
Mar 20, 2015 SOUTH SAN FRANCISCO, Calif., March 20, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced that it has entered into definitive agreements with institutional investors to purchase an aggregate of $10 million of registered shares of OXiGENE com...
Mar 17, 2015 - Strong Year-End Cash Balance of $30 Million - - Significant R&D Milestones Anticipated in 2015 - SOUTH SAN FRANCISCO, Calif., March 17, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, reported financial results for the year ended Decemb...
Mar 4, 2015 SOUTH SAN FRANCISCO, Calif., March 4, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will report year-end 2014 results on Tuesday March 17, 2015. A conference call and webcast hosted by OXiGENE management will begin at 4:30 pm ET (1:30 p.m. PT). ...
Feb 24, 2015 SOUTH SAN FRANCISCO, Calif., Feb. 24, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel cancer therapeutics, announced that Dai Chaplin, Ph.D., president and chief executive officer, will provide a corporate overview at the 27th Annual ROTH Conference on March 11, 2015. The presentatio...
Jan 26, 2015 SOUTH SAN FRANCISCO, Calif., Jan. 26, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel cancer therapeutics, announced that David Chaplin, Ph.D., president and chief executive officer, will provide a corporate overview at the 17th Annual BIO CEO & Investor conference on February 10, 20...
Nov 20, 2014 SOUTH SAN FRANCISCO, Calif., Nov. 20, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel cancer therapeutics, today announced that a poster presentation related to its clinical stage product candidate, OXi4503, will be presented at the American Society of Hematology (ASH) annual meeting taking place D...
Page:
1
... NextLast
= add release to Briefcase